A Phase I Study of SGN-STNV in People with Advanced Solid Tumors

Share

Full Title

A Phase 1 Study of SGN-STNV in Advanced Solid Tumors

Purpose

The purpose of this study is to find the highest dose of the investigational drug SGN-STNV that can be given safely in people with advanced solid tumors that have come back or continued to grow despite treatment.

SGN-STNV is a type of drug called an antibody-drug conjugate (ADC). It is made up of a protein called an antibody and a chemotherapy drug. The antibody binds to a protein called STn that exists on some cancer cells. When the antibody attaches to a cancer cell, the chemotherapy drug enters the cell, causing damage to the cell that may slow or stop the growth of the cancer. SGN-STNV is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have an advanced cancer (non-small cell lung or ovarian) that has come back or continued to grow despite treatment.
  • At least 4 weeks must pass between the completion of prior treatment and receipt of the study therapy.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr. Claire Friedman at 646-888-4226.

Protocol

22-279

Phase

I

Investigator

Co-Investigators